Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Clinical and genetic characterization of hereditary breast cancer in a Chinese population.

Jian W, Shao K, Qin Q, Wang X, Song S, Wang X.

Hered Cancer Clin Pract. 2017 Oct 30;15:19. doi: 10.1186/s13053-017-0079-4. eCollection 2017.

2.

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.

PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.

3.

Comprehensive benchmarking of SNV callers for highly admixed tumor data.

Bohnert R, Vivas S, Jansen G.

PLoS One. 2017 Oct 11;12(10):e0186175. doi: 10.1371/journal.pone.0186175. eCollection 2017.

4.

Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.

Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP.

Oncotarget. 2017 Mar 3;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 1.

5.

Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.

Gayarre J, Martín-Gimeno P, Osorio A, Paumard B, Barroso A, Fernández V, de la Hoya M, Rojo A, Caldés T, Palacios J, Urioste M, Benítez J, García MJ.

Br J Cancer. 2017 Sep 26;117(7):1048-1062. doi: 10.1038/bjc.2017.286. Epub 2017 Aug 22.

PMID:
28829762
6.

Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.

Sato K, Koyasu M, Nomura S, Sato Y, Kita M, Ashihara Y, Adachi Y, Ohno S, Iwase T, Kitagawa D, Nakashima E, Yoshida R, Miki Y, Arai M.

Cancer Sci. 2017 Nov;108(11):2287-2294. doi: 10.1111/cas.13350. Epub 2017 Sep 18.

7.

FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.

Kiiski JI, Tervasmäki A, Pelttari LM, Khan S, Mantere T, Pylkäs K, Mannermaa A, Tengström M, Kvist A, Borg Å, Kosma VM, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Winqvist R, Nevanlinna H.

Breast Cancer Res Treat. 2017 Nov;166(1):217-226. doi: 10.1007/s10549-017-4388-0. Epub 2017 Jul 12.

8.

Germline Mutations in Triple-Negative Breast Cancer.

Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK.

Breast Care (Basel). 2017 Mar;12(1):15-19. doi: 10.1159/000455999. Epub 2017 Feb 24. Review.

PMID:
28611536
9.

Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.

Stafford JL, Dyson G, Levin NK, Chaudhry S, Rosati R, Kalpage H, Wernette C, Petrucelli N, Simon MS, Tainsky MA.

PLoS One. 2017 Jun 7;12(6):e0178450. doi: 10.1371/journal.pone.0178450. eCollection 2017.

10.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

11.

GT198 (PSMC3IP) germline variants in early-onset breast cancer patients from hereditary breast and ovarian cancer families.

Schubert S, Ripperger T, Rood M, Petkidis A, Hofmann W, Frye-Boukhriss H, Tauscher M, Auber B, Hille-Betz U, Illig T, Schlegelberger B, Steinemann D.

Genes Cancer. 2017 Jan;8(1-2):472-483. doi: 10.18632/genesandcancer.132.

12.

Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.

Mills K, Fuh K.

F1000Res. 2017 Jan 27;6:84. doi: 10.12688/f1000research.9977.1. eCollection 2017. Review.

13.

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

Ghiringhelli F, Richard C, Chevrier S, Végran F, Boidot R.

World J Gastroenterol. 2016 Dec 28;22(48):10680-10686. doi: 10.3748/wjg.v22.i48.10680.

14.

The homologous recombination protein RAD51D protects the genome from large deletions.

Reh WA, Nairn RS, Lowery MP, Vasquez KM.

Nucleic Acids Res. 2017 Feb 28;45(4):1835-1847. doi: 10.1093/nar/gkw1204.

15.

The MMS22L-TONSL heterodimer directly promotes RAD51-dependent recombination upon replication stress.

Piwko W, Mlejnkova LJ, Mutreja K, Ranjha L, Stafa D, Smirnov A, Brodersen MM, Zellweger R, Sturzenegger A, Janscak P, Lopes M, Peter M, Cejka P.

EMBO J. 2016 Dec 1;35(23):2584-2601. Epub 2016 Oct 26.

PMID:
27797818
16.

Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia.

Mamrak NE, Shimamura A, Howlett NG.

Blood Rev. 2017 May;31(3):93-99. doi: 10.1016/j.blre.2016.10.002. Epub 2016 Oct 13. Review.

PMID:
27760710
17.

Estrogen induces RAD51C expression and localization to sites of DNA damage.

Alayev A, Salamon RS, Manna S, Schwartz NS, Berman AY, Holz MK.

Cell Cycle. 2016 Dec;15(23):3230-3239. Epub 2016 Oct 18.

18.

Mechanism and disease association of E2-conjugating enzymes: lessons from UBE2T and UBE2L3.

Alpi AF, Chaugule V, Walden H.

Biochem J. 2016 Oct 15;473(20):3401-3419. Review.

19.
20.

The biological effects and clinical implications of BRCA mutations: where do we go from here?

Stoppa-Lyonnet D.

Eur J Hum Genet. 2016 Sep;24 Suppl 1:S3-9. doi: 10.1038/ejhg.2016.93. Review.

Supplemental Content

Support Center